| EDITORIALS |
| 1 | Triaging treatable traits in asthma
|
| 5 | What triggers acute exacerbations of COPD? Why not ask the patient!
|
| 7 | Towards a refined definition of combined pulmonary fibrosis and emphysema
|
| 9 | Predicting response to bronchial thermoplasty in patients with severe uncontrolled asthma: An elusive goal
|
| 11 | Clinical utility of pulmonary function and blood biomarker measurements
|
| COMMENTARIES |
| 13 | Targeting reactive oxygen species for respiratory infection: Fact or fancy?
|
| 15 | Remarkable progress in cystic fibrosis – But why?
Catherine Rang BA(Hons), MB BChir, MA, MRCP; John Wilson AM, BSc(Hons), PhD, MBBS, FRACP
10.1111/resp.13440 |
| INVITED REVIEW SERIES |
| Molecular Techniques for Respiratory Diseases |
| 17 | The contribution of respiratory microbiome analysis to a treatable traits model of care
Steven L Taylor Hannah E O'Farrell Jodie L Simpson Ian A Yang Geraint B Rogers
10.1111/resp.13411 |
| 19 | Transcriptomics and single-cell RNA-sequencing
|
| ORIGINAL ARTICLES |
| Asthma and Allergy |
| 29 |
Treatable traits can be identified in a severe asthma registry and predict future exacerbations
Vanessa M McDonald, Sarah A Hiles, Krystelle Godbout, Erin S Harvey, Guy B Marks, Mark Hew, Matthew Peters, Philip G Bardin, Paul N Reynolds, John W Upham, Melissa Baraket, Zaheerodin Bhikoo, Jeffrey Bowden, Ben Brockway, Li Ping Chung, Belinda Cochrane, Gloria Foxley, Jeffrey Garrett, Lata Jayaram, Christine Jenkins, Constance Katelaris, Gregory Katsoulotos, Mariko S Koh, Vicky Kritikos, Marina Lambert, David Langton, Alexis Lara Rivero, Peter G Middleton, Aldoph Nanguzgambo, Naghmeh Radhakrishna, Helen Reddel, Janet Rimmer, Anne Marie Southcott, Michael Sutherland, Francis Thien, Peter A B Wark, Ian A Yang, Elaine Yap, Peter G Gibson
10.1111/resp.13389
We assessed the prevalence of treatable traits in severe asthma compared with non-severe asthma, and assessed the relationship between treatable traits and future exacerbation risk. We demonstrate the usefulness of the treatable traits approach in severe asthma and which specific treatable traits are predictive of future asthma attacks.  |
| COPD |
| 37 | Towards an assessment of perceived COPD exacerbation triggers: Initial development and validation of a questionnaire
Chelsey A Werchan, Ashton M Steele, Thomas Janssens, Mark W Millard, Thomas Ritz
10.1111/resp.13368
The present study sought to develop a psychometrically valid measure of perceived triggers of exacerbations in chronic obstructive pulmonary disease (COPD) patients, the COPD Exacerbation Trigger Inventory (CETI). Patients' trigger classes and their controllability are associated with clinical outcomes and their assessment may prove useful in research and clinical settings with COPD patients, aiding exacerbation prevention and disease management. |
| Interstitial Lung Disease |
| 48 |
Effects of emphysema on physiological and prognostic characteristics of lung function in idiopathic pulmonary fibrosis
Hee-Young Yoon, Tae Hoon Kim, Joon Beom Seo, Sang Min Lee, Soyeoun Lim, Han Na Lee, Namkug Kim, Minkyu Han, Dong Soon Kim, Jin Woo Song
10.1111/resp.13387
Patients with idiopathic pulmonary fibrosis (IPF) and emphysema exceeding 10% had more preserved lung volume and lower rates of decline in forced vital capacity (FVC) than those with no or trivial emphysema. Diffusing capacity of the lung for carbon monoxide (DLCO) was the most significant prognostic factor in these patients. |
| Interventional Pulmonology |
| 55 | Bronchodilator responsiveness as a predictor of success for bronchial thermoplasty
David Langton, Alvin Ing, David Fielding, Wei Wang, Virginia Plummer, Francis Thien
10.1111/resp.13375
This study, in patients with severe asthma, compares the outcomes from bronchial thermoplasty (BT) in patients with fixed airflow obstruction, with patients with bronchodilator reversibility. The study concludes that both groups of patients benefit equally well from this therapy and that bronchodilator reversibility need not be a selection criterion for BT. |
| Lung Function |
| 63 | Decline in lung function is associated with elevated lipoprotein (a) in individuals without clinically apparent disease: A cross-sectional study
Jonghoo Lee, Hye Kyeong Park, Min-Jung Kwon, Jae-Uk Song
10.1111/resp.13370
Reduced lung function and high Lp(a) levels are risk factors for cardiovascular disease (CVD). High Lp(a) levels were associated with reduced lung function in this large study. Thus, Lp(a) may be the link between increased CVD risk and reduced lung function. |
| Pleural Disease |
| 68 | Risk factors for pleural effusion recurrence in patients with malignancy
Horiana B Grosu, Sofia Molina, Roberto Casal, Juhee Song, Liang Li, Javier Diaz-Mendoza, Chakravarthy Reddy, Lonny Yarmus, Dante Schiavo, Michael Simoff, Jared Johnstun, Abu-Awwad Raid, David Feller-Kopman, Hans Lee, Sarina Sahetya, Finbar Foley, Fabien Maldonado, Xin Tian, Laila Noor, Russell Miller, Lakshmi Mudambi, Timothy Saettele, Macarena Vial-Rodriguez, Gerogie A Eapen, David E Ost
10.1111/resp.13362
Factors such as larger pleural effusion size, amount of pleural fluid drained, LDH and pleural fluid cytology were found to be risk factors for pleural fluid recurrence. Knowing what risk factors are associated with recurrence of pleural effusion would allow physicians to identify patients who are more likely to recur. |
| LETTER FROM ASIA-PACIFIC REGION |
| 76 | Letter from Vietnam
|
| CORRIGENDUM |
| 83 | This article corrects doi.org/10.1111/resp.12486
|
